Literature DB >> 11861115

Structure elucidation and conformational properties of eprosartan, a non peptide angiotensin II AT1 antagonist.

Panagiotis Zoumpoulakis1, Simona Golic Grdadolnik, John Matsoukas, Thomas Mavromoustakos.   

Abstract

A novel approach to treat hypertension is to interfere with the Renin-Angiotensin system (RAS) by blocking the binding of vasoconstrictive hormone Angiotensin II to the AT(1) receptor site. This approach led to the beneficial drug losartan (COZAAR) and other similar in structure to the antihypertensive drugs (sartans). In an effort to compare the stereoelectronic features of pharmacophoric segments of the different sartans, a research activity was initiated in our laboratory related to the conformational properties of these drugs. In a previous study, the structural features which determine the pharmacophoric segments of losartan were examined. In this study, the conformational properties of eprosartan (TEVETEN), a drug with fewer side effects, were examined. In addition, the superimposition ability of losartan and eprosartan with the peptide antagonist sarmesin was studied.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11861115     DOI: 10.1016/s0731-7085(01)00603-3

Source DB:  PubMed          Journal:  J Pharm Biomed Anal        ISSN: 0731-7085            Impact factor:   3.935


  2 in total

1.  Development of a CP 31P NMR broadline simulation methodology for studying the interactions of antihypertensive AT1 antagonist losartan with phospholipid bilayers.

Authors:  Charalambos Fotakis; Dionisios Christodouleas; Petros Chatzigeorgiou; Maria Zervou; Nikolas-Ploutarch Benetis; Kyriakos Viras; Thomas Mavromoustakos
Journal:  Biophys J       Date:  2009-03-18       Impact factor: 4.033

Review 2.  On the Rational Drug Design for Hypertension through NMR Spectroscopy.

Authors:  Eleni Chontzopoulou; Andreas G Tzakos; Thomas Mavromoustakos
Journal:  Molecules       Date:  2020-12-22       Impact factor: 4.411

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.